Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
ÌÇÐÄ´«Ã½
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Strosberg, J. R., Zemla, T. J., Geyer, S., Knopp, M. V., Behr, S., Pulsipher, S., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T., Konda, B., Trikalinos, N., Tawfik, B., Raj, N., Shaheen, S., Vijayvergia, N., Dasari, A., O'Reilly, E. M., Meyerhardt, J. A., Chan, J. A. LIPPINCOTT WILLIAMS & WILKINS. 2025: 666View details for
View details for